AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06249854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bojungikki-tang(BJIKT)
Description: Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time, has been reported to have following anticancer activities.~1. Protective effect of intestine and hematopoietic organs against radiation damage~2. Improving localized radiotherapy-induced immune deterioration~3. Improving cancer-related fatigue and QOL~4. Reducing radiation or chemotherapy induced side effects
Study NCT06249854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: It is a humanized antibody used in cancer immunotherapy for various types of cancer, including lung cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the U.S. in 2014.
Study NCT06249854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: It is a humanized antibody used in cancer immunotherapy for various types of cancer, including lung cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the U.S. in 2014.
Study NCT06619262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS stands for transcutaneous electrical nerve stimulation. Transcutaneous means across the skin. TENS machines pass a small electrical current across your skin to stimulate the nerves.
Study NCT06619262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS stands for transcutaneous electrical nerve stimulation. Transcutaneous means across the skin. TENS machines pass a small electrical current across your skin to stimulate the nerves.
Study NCT06619262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular and Muscular Electrical Stimulation
Description: Neuromuscular and Muscular Electrical Stimulation (NMES) is a modality that sends electrical impulses to nerves which causes the muscles to contract mimicking the action potential coming from the central nervous system.
Study NCT06619262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular and Muscular Electrical Stimulation
Description: Neuromuscular and Muscular Electrical Stimulation (NMES) is a modality that sends electrical impulses to nerves which causes the muscles to contract mimicking the action potential coming from the central nervous system.
Study NCT06619262 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise program
Description: Specific exercise program for patients with lower extremity hemiparesis after stroke
Study NCT06619262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Specific exercise program for patients with lower extremity hemiparesis after stroke
Study NCT06619262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Specific exercise program for patients with lower extremity hemiparesis after stroke
Study NCT04889157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)
Study NCT04889157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
Study NCT05499260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB03-154
Description: CB03-154 tablet once daily.
Study NCT05499260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.
Study NCT04889196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)
Study NCT04889196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hall technique
Description: The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
Study NCT04743804 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
Study NCT04743804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT04743804 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Study NCT04743804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Study NCT06385340 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lipikar Baume AP+M
Description: • Lipikar Baume AP+M Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme
Study NCT05769868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol Injection [Brevibloc]
Description: Brevibloc® will be administered intravenously by infusion pump following the administration schedule:~Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes.~If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute.~The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg.~The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min).
Study NCT05157542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Day 1 and 22, 1500mg
Study NCT05157542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin bound paclitaxel
Description: Day1 and 22 nanoparticle albumin-bound paclitaxel 260 mg/m2 and carboplatin AUC 5
Study NCT05157542 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose radiation therapy
Description: 10 Gy in 5 fractions, 20 Gy in 10 fractions, 30 Gy in 15 fractions respectively in our three groups from Day1
Study NCT04378959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Description: Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
Study NCT04378959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine patch
Description: Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
Study NCT04378959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
Study NCT04378959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
Study NCT05672407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 100 mg/mL Tranexamic acid with lidocaine with 1:100,000 epinephrine in 1:1 manner administered subcutaneously
Study NCT05672407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lidocaine with 1:100,000 epinephrine mixed with 1:1 Basal Saline Solution (BSS) administered subcutaneously
Study NCT04888403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab+Nedaplatin+Albumin Paclitaxel
Description: Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel
Study NCT05176626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Lifestyle Behavioral Therapy
Description: Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
Study NCT05176626 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Online Lifestyle Behavioral Therapy
Description: Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.
Study NCT05176626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine Hydrochloride 8 MG
Description: At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
Study NCT04875390 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Erector spina plane block
Description: After the surgery is completed, intraoperative Erector spina plane block will be performed
Study NCT04875390 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: local infiltration
Description: After the surgery is completed, intraoperative local infiltration will be performed
Study NCT05860725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSA Development
Description: Health sciences students from a regional community college in Appalachian Virginia will be asked to to develop and submit a public service announcement (PSA) and to watch virtual training webinars that support the development of the PSAs. They will also be asked to complete surveys at three time points: before the PSA contest starts, after the PSA contest ends, and upon submitting a PSA.
Study NCT05860725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV vaccination focused social marketing campaign
Description: Community members who use a regional health services focused non-profits rideshare buses and/or view their social media pages will be exposed to a 12-week social marketing campaign that uses PSAs developed in Phase 1. Community members will also complete surveys at three time points: before the start of the social marketing campaign, during the social marketing campaign, and after the social marketing campaign.
Study NCT05099016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint Effort
Description: The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and 14) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.
Study NCT05099016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief normative feedback and standard information
Description: The brief normative feedback is based on the frequency of cannabis use use. Participants will also be offered basic reliable non personalized information on lower-risk cannabis use in the form of official public websites.
Study NCT06017687 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OptiBP Study app
Description: Each participant will use OptiBP Study app to measure their blood pressure optically by applying their fingertip to their smartphone camera, and subsequently enter the blood pressure values obtained by measuring it with their own blood pressure cuff.
Study NCT06525753 — intervention group
Intervention type: OTHER
Intervention: Weaning off Parenteral Nutrition
Description: pediatric intestinal failure patients who have been weaned off parenteral nutrition
Study NCT05680298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: solution for injection, Subcutaneous injection
Study NCT05936203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin therapy adjustment
Description: Strategies used to manage glucose control during a prolonged aerobic exercise
Study NCT04593095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroN-QI
Description: SSC session lasting 2-hr during the day 4 times/wk including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise followed by a 1-hr quiet period where infants will rest in their incubator/crib with olfactory stimulation and where the control of light and noise levels will be continued.
Study NCT04943302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: To be given by IV at 70mg/m2 on cycle days 1 and 8 for up to 6 cycles
Study NCT04943302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: To be given by IV at10mg/kg IV on cycle 1 days 1,8,15, and 22; cycle 2-6 days 1,8; and cycle 7-12 days 1
Study NCT06137703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 100mg non-enteric coated soft gel capsule
Description: Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule
Study NCT06137703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 100mg immediate release tablet
Description: Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet
Study NCT06137703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 2 x 100mg immediate release tablets
Description: 2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg
Study NCT06137703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zavegepant 4 x 25mg enteric coated soft gel capsule
Description: Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg
Study NCT05930028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Subjects take the investigational products once a day for 8 weeks.
Study NCT05930028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan
Description: Subjects take the investigational products once a day for 8 weeks.
Study NCT05930028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe/Atorvastatin
Description: Subjects take the investigational products once a day for 8 weeks.
Study NCT05930028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe/Atorvastatin
Description: Subjects take the investigational products once a day for 8 weeks.
Study NCT05930028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan Placebo
Description: Subjects take the investigational products once a day for 8 weeks.
Study NCT05930028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe/Atorvastatin Placebo
Description: Subjects take the investigational products once a day for 8 weeks.
Study NCT05759429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BWRP
Description: Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP, which includes a low-calorie diet, physical activity, psychological support, and nutritional education
Study NCT05759429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BWRP + melatonin
Description: Physical exercise protocol after 1 and 15 days of integrated multidisciplinary BWRP and melatonin (4 mg/die), administered 2-3 hours before bedtime
Study NCT04514744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Knee bracing
Description: Participants will have one leg immobilized, by means of a removable Don Joy Knee Brace. Participants will be expected to keep the knee brace on for 14 days, completely prevent weight bearing on the immobilized leg, and use crutches.
Study NCT04514744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Resistance Exercise Training
Description: Participants will perform resistance training on 4 occasions throughout an 8 day time period.
Study NCT05831839 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RehaCom
Description: computerized cognitive training
Study NCT05936203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional adjustment
Description: Strategies used to manage glucose control during a prolonged aerobic exercise
Study NCT05936203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of strategies
Description: Strategies used to manage glucose control during a prolonged aerobic exercise
Study NCT05601921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive intervention that uses magnetic fields to stimulate nerve cells to improve the symptoms of a variety of disorders. In recent years, TMS studies have been conducted in many painful conditions, which are thought to have complex pain mechanisms in the pathogenesis, and its effectiveness has been reported.
Study NCT05601921 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial magnetic stimulation
Description: Sham Repetitive transcranial magnetic stimulation
Study NCT06305689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical procedure to the gastrocnemius and/or plantar fascia
Study NCT06305689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serial Casting
Description: Repeated casts weekly until desired dorsiflexion range achieved
Study NCT06183086 — intervention group
Intervention type: DEVICE
Intervention: Linovera®
Description: Apply Linovera® at least twice a day (recommended every 12 h) on the pressure ulcer/injury until Category-1 pressure ulcer/injury is healed or until discharge.
Study NCT03806413 — intervention group
Intervention type: OTHER
Intervention: Open heart surgery
Description: The study will be done on patients undergoing open heart surgery in Alexandria University hospitals from January 5th 2019 till January 4th 2020. The 6-item Cognitive Impairment Test (6CIT) and SPMSQ questionnaire will be used. SPMSQ will be done preoperative and daily for 3 days postoperative, at day 7. Phone call for SPMSQ will be done 3, 6 9 and 12 months after surgery.
Study NCT04814615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-daratumumab PET/CT
Description: CD38-targeting imaging
Study NCT05289284 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04764929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Description: Vyatil nonpowered oxygen tent system
Study NCT05620030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Univentricular Heart
Description: Prevention of complications when discovered
Study NCT05582213 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: induction of anesthesia
Description: This group includes (20) patients will receive induction by sevoflurane 3% using open circuit (modified Ayre's T-piece) till loss of consciousness and will be maintained on oxygen mask on the same concentration of sevoflurane and connected to capnogram